Lantheus (NASDAQ:LNTH) Issues Quarterly Earnings Results

Key Points

• Lantheus reported a quarterly EPS of $1.57, missing the consensus estimate of $1.65 by $0.08, with revenue of $378.05 million, down 4.1% year-over-year.
• The stock trades at $57.20, with a market capitalization of $3.96 billion and a PE ratio of 15.21, reflecting a significant drop from its 1-year high of $118.21.
• A number of analysts have decreased their price targets for Lantheus, with the current consensus rating being "Moderate Buy" and an average price target of $114.50.

Lantheus (NASDAQ:LNTH - Get Free Report) released its quarterly earnings data on Wednesday. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08), Briefing.com reports. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $378.05 million during the quarter, compared to analysts' expectations of $389.69 million. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The firm's quarterly revenue was down 4.1% on a year-over-year basis.

Lantheus Stock Down 4.4%

Shares of NASDAQ:LNTH traded down $2.49 during midday trading on Tuesday, reaching $53.58. The company had a trading volume of 1,766,055 shares, compared to its average volume of 1,138,569. The stock's fifty day moving average price is $75.89 and its 200-day moving average price is $86.49. Lantheus has a one year low of $47.25 and a one year high of $118.21. The stock has a market capitalization of $3.64 billion, a P/E ratio of 14.23 and a beta of 0.14. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on LNTH shares. B. Riley reduced their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Mizuho cut their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, August 7th. Truist Financial set a $63.00 price objective on shares of Lantheus and gave the company a "hold" rating in a report on Monday. Finally, Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $105.50.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.00% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.